Renaissance Technologies LLC Has $33.70 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Renaissance Technologies LLC boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 15.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,175,727 shares of the biopharmaceutical company’s stock after purchasing an additional 287,300 shares during the period. Renaissance Technologies LLC owned about 1.84% of Catalyst Pharmaceuticals worth $33,702,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 3.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 956,333 shares of the biopharmaceutical company’s stock valued at $16,076,000 after buying an additional 35,006 shares during the period. Dimensional Fund Advisors LP increased its position in Catalyst Pharmaceuticals by 1.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company’s stock valued at $43,738,000 after purchasing an additional 41,923 shares during the period. UBS Group AG increased its position in Catalyst Pharmaceuticals by 37.7% during the 4th quarter. UBS Group AG now owns 469,316 shares of the biopharmaceutical company’s stock valued at $7,889,000 after purchasing an additional 128,595 shares during the period. Assetmark Inc. raised its holdings in Catalyst Pharmaceuticals by 4.0% during the 4th quarter. Assetmark Inc. now owns 64,678 shares of the biopharmaceutical company’s stock worth $1,087,000 after purchasing an additional 2,505 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Catalyst Pharmaceuticals by 21.9% in the 4th quarter. Franklin Resources Inc. now owns 185,923 shares of the biopharmaceutical company’s stock worth $3,125,000 after purchasing an additional 33,397 shares during the period. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Trading Down 0.0 %

Catalyst Pharmaceuticals stock opened at $20.43 on Thursday. The firm’s fifty day moving average price is $18.71 and its two-hundred day moving average price is $16.75. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of 37.83, a price-to-earnings-growth ratio of 3.10 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.55 and a 1-year high of $20.87.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. The business had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. On average, research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Citigroup lifted their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, HC Wainwright increased their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $29.50.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the transaction, the insider now directly owns 12,369 shares in the company, valued at approximately $227,836.98. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares in the company, valued at approximately $227,836.98. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 201,058 shares of company stock worth $4,018,188. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.